nafamostat has been researched along with Cytokine Release Syndrome in 2 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms." | 2.72 | COVID-19-associated coagulopathy and disseminated intravascular coagulation. ( Asakura, H; Ogawa, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, H | 1 |
| Fang, Y | 1 |
| Xu, T | 1 |
| Ni, WJ | 1 |
| Shen, AZ | 1 |
| Meng, XM | 1 |
| Asakura, H | 1 |
| Ogawa, H | 1 |
2 reviews available for nafamostat and Cytokine Release Syndrome
| Article | Year |
|---|---|
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En | 2020 |
COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Topics: Adult; Anticoagulants; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Tests; COVID-19; | 2021 |